These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 13715278)

  • 1. [DURATION OF DISEASE AND SURVIVAL TIME IN MULTIPLE MYELOMA].
    OBRECHT P; KALLITERAKIS E; KLEMM D
    Klin Wochenschr; 1963 Sep; 41():891-8. PubMed ID: 14054439
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. I. Plan of study.
    BERGSAGEL DE; SPRAGUE CC; ROSS SW
    Cancer Chemother Rep; 1962 Aug; 21():69-74. PubMed ID: 13867795
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experience with the use of sarcolysin in multiple myeloma].
    ALEKSEEV GA; PETROV KIa
    Probl Gematol Pereliv Krovi; 1961 Dec; 6():3-10. PubMed ID: 13860267
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. VI. Metasarcolysin.
    AUSTIN C; BERGSAGEL DE; SPRAGUE CC
    Cancer Chemother Rep; 1962 Aug; 21():107-12. PubMed ID: 13863325
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. III. AB-100 (NSC-37095).
    BROWN CL; BERGSAGEL DE; LEVIN WC
    Cancer Chemother Rep; 1962 Aug; 21():81-5. PubMed ID: 13873596
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. 1-Aminocyclopentanecarboxylic acid (NSC-1026).
    BERGSAGEL DE; ROSS SW; BAKER DT
    Cancer Chemother Rep; 1962 Aug; 21():101-6. PubMed ID: 13867792
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study of optimal medical care with and without azaserine in multiple myeloma.
    HOLLAND JF
    Clin Pharmacol Ther; 1961; 2():22-8. PubMed ID: 13715278
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple myeloma].
    Hsu DC; Wilkenfeld P; Joshua DE
    Praxis (Bern 1994); 2012 Jun; 101(13):857-61. PubMed ID: 22715077
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple myeloma--an update on diagnosis and treatment.
    Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
    Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution and impact of therapy in multiple myeloma.
    Laubach JP; Richardson PG; Anderson KC
    Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standard therapy for multiple myeloma].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2012 Oct; 53(10):1675-88. PubMed ID: 23037740
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.